J. Erfán

543 total citations
9 papers, 349 citations indexed

About

J. Erfán is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Erfán has authored 9 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Otorhinolaryngology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Erfán's work include Head and Neck Cancer Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (2 papers). J. Erfán is often cited by papers focused on Head and Neck Cancer Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and HER2/EGFR in Cancer Research (2 papers). J. Erfán collaborates with scholars based in Hungary, Belgium and Spain. J. Erfán's co-authors include Éva Remenár, Ricard Mesı́a, Sylvie Rottey, Ricardo Hitt, Marco Benasso, Andrzej Kawecki, JB Vermorken, Fernando Rivera, Stephan Störkel and Christopher Stroh and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Investigational New Drugs.

In The Last Decade

J. Erfán

9 papers receiving 345 citations

Peers

J. Erfán

ONCOL

PRM

OTORH

SURGE

Kaisa Erjala Finland

Lorian Menkema Netherlands

Max Partridge United Kingdom

Hiroe Tada Japan

Albiruni R. Abdul Razak Canada

Robert Konschak Germany

Maria Anderson United States

David A. Clump United States

Ben Robinson United Kingdom

Hyun-Bae Jie United States

Kaisa Erjala Finland

J. Erfán

218 ×1.0

ONCOL

135 ×0.9

PRM

88 ×0.6

OTORH

158 ×1.4

28 ×0.4

SURGE

Citations per year, relative to J. Erfán J. Erfán (= 1×) peers Kaisa Erjala

Countries citing papers authored by J. Erfán

Since Specialization

Citations

This map shows the geographic impact of J. Erfán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Erfán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Erfán more than expected).

Fields of papers citing papers by J. Erfán

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Erfán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Erfán. The network helps show where J. Erfán may publish in the future.

Co-authorship network of co-authors of J. Erfán

This figure shows the co-authorship network connecting the top 25 collaborators of J. Erfán. A scholar is included among the top collaborators of J. Erfán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Erfán. J. Erfán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lidbrink, Elisabet, J. Erfán, Ewa Chmielowska, et al.. (2017). OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis. Annals of Oncology. 28. v52–v52. 2 indexed citations

Lidbrink, Elisabet, J. Erfán, Ewa Chmielowska, et al.. (2017). 1348P Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies.. 2 indexed citations

Ruzsa, Ágnes, Mehmet Şen, Mark D. Evans, et al.. (2014). Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Investigational New Drugs. 32(6). 1278–1284. 46 indexed citations

Vermorken, Jan B., Frédéric Peyrade, John C. Krauss, et al.. (2014). Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Annals of Oncology. 25(3). 682–688. 76 indexed citations

Muñoz-Mateu, Montserrat, Ander Urruticoechea, Robert Šeparović, et al.. (2011). Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).. Journal of Clinical Oncology. 29(15_suppl). TPS118–TPS118. 9 indexed citations

Licitra, Lisa, Ricard Mesı́a, Fernando Rivera, et al.. (2010). Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Annals of Oncology. 22(5). 1078–1087. 178 indexed citations

Vermorken, Jan B., Ricardo Hitt, Lionnel Geoffrois, et al.. (2007). 5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME). European Journal of Cancer Supplements. 5(4). 324–324. 18 indexed citations

Vermorken, J. B., Ricard Mesı́a, M. E. Vega-Villegas, et al.. (2006). Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). Journal of Clinical Oncology. 24(18_suppl). 5537–5537. 17 indexed citations

Ésik, Olga, et al.. (1995). [Quality assurance, audit and quality control of radiotherapy at radiology departments in Hungary].. PubMed. 136(45). 2441–51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact